Abstract:Introdução: A carcinogênese caracteriza-se como um processo multifatorial, e a inativação da proteína p53 é uma alteração genética comumente observada nos carcinomas de células escamosas de boca (CCEB). Objetivo: Analisar e comparar a imunoexpressão da proteína p53, por meio dos clones DO-7 e PAb-240, em CCEB com localização intrabucal e em lábio inferior. Material e métodos: Foram selecionados 40 casos de CCEB, sendo 20 de localização intrabucal e 20 em lábio inferior. Foi realizado um estudo imuno-histoquími… Show more
“…On the basis of these findings, it can be inferred that PAb-240 antibody may be more useful to recognize the mutant form of p53 protein, although most published studies [11,23,27,32] use the DO-7 clone. Our previous study with oral cavity and lip squamous cell carcinomas with both antibodies also supports these findings [26]. Conflicting results presented in different studies could reflect differences in antibody specificities used, but also in assay methods.…”
Section: Discussionsupporting
confidence: 75%
“…The majority of studies about p53 in OSCC have focused on protein expression by immunohistochemistry [6,8,9,10,11,17]. Some of these studies [22,23,24] include tumors affecting head and neck cancer as a whole, others are more specific and analyze p53 expression only in the mouth [25,26,27]. In the present study a population of patients diagnosed with primary OSCC was analyzed in order to obtain a more specific result.…”
Background/Aim: The TP53 gene is a tumor suppressor gene. Its product is a nuclear protein that regulates cell cycle arrest, apoptosis and DNA repair. Anti-p53 clones DO-7 and PAb-240 recognize the amino acid sequences 21-25 and 213-217, respectively. This study aimed to evaluate the expression of these clones and their relationship with clinicopathological features and survival analysis in oral squamous cell carcinomas (OSCC). Methods: Information on 53 primary OSCC was collected at the Brazilian National Cancer Institute. An immunohistochemical method was applied to evaluate p53 expression (DO-7 and PAb-240). Their expression was analyzed quantitatively and correlated with clinicopathological features. Kaplan-Meier survival curves and log rank test were used. Results: Immunopositivity for DO-7 was present in 64% of the cases, while 58% were positive for PAb-240. There was no correlation between immunoexpression of both antibodies and clinicopathological features or survival analysis. DO-7 expression was significantly higher (p = 0.001) than that of PAb-240. Conclusions: There were quantitative differences between the expression of the antibodies studied, which may reflect a different specificity of each one. To confirm immunohistochemical results and estimate the true prognostic role of TP53 in OSCC, it is important to perform mutation analysis.
“…On the basis of these findings, it can be inferred that PAb-240 antibody may be more useful to recognize the mutant form of p53 protein, although most published studies [11,23,27,32] use the DO-7 clone. Our previous study with oral cavity and lip squamous cell carcinomas with both antibodies also supports these findings [26]. Conflicting results presented in different studies could reflect differences in antibody specificities used, but also in assay methods.…”
Section: Discussionsupporting
confidence: 75%
“…The majority of studies about p53 in OSCC have focused on protein expression by immunohistochemistry [6,8,9,10,11,17]. Some of these studies [22,23,24] include tumors affecting head and neck cancer as a whole, others are more specific and analyze p53 expression only in the mouth [25,26,27]. In the present study a population of patients diagnosed with primary OSCC was analyzed in order to obtain a more specific result.…”
Background/Aim: The TP53 gene is a tumor suppressor gene. Its product is a nuclear protein that regulates cell cycle arrest, apoptosis and DNA repair. Anti-p53 clones DO-7 and PAb-240 recognize the amino acid sequences 21-25 and 213-217, respectively. This study aimed to evaluate the expression of these clones and their relationship with clinicopathological features and survival analysis in oral squamous cell carcinomas (OSCC). Methods: Information on 53 primary OSCC was collected at the Brazilian National Cancer Institute. An immunohistochemical method was applied to evaluate p53 expression (DO-7 and PAb-240). Their expression was analyzed quantitatively and correlated with clinicopathological features. Kaplan-Meier survival curves and log rank test were used. Results: Immunopositivity for DO-7 was present in 64% of the cases, while 58% were positive for PAb-240. There was no correlation between immunoexpression of both antibodies and clinicopathological features or survival analysis. DO-7 expression was significantly higher (p = 0.001) than that of PAb-240. Conclusions: There were quantitative differences between the expression of the antibodies studied, which may reflect a different specificity of each one. To confirm immunohistochemical results and estimate the true prognostic role of TP53 in OSCC, it is important to perform mutation analysis.
“…Digital Pathology systems have been used in Latin America for morphometric analysis (Sanz Pupo et al 2006), histology (Araújo et al 2009), histochemistry (Melo-Júnior et al 2006, immunohistochemistry (Araújo-Filho et al 2006;Silva Júnior et al 2009), neuropathology (Peixoto-Santos and Blumcke 2021), medical education (Monteiro et al 2015;Pérez et al 2016), and reproducibility research (Schettini et al 2011). Besides those reports, the experts in the panel also report utilizing DP systems for measurements of cancer invasive borders, static cytometry, intra-operatory biopsy analyses, creation of digital archives, telepathology, research, publications, and videoconferencing.…”
Section: Current Dp Uses In Latin Americamentioning
Digital pathology (DP) adoption in Latin America has expanded slower than in developed regions, probably due to many barriers not seen in the latter areas. This article aims to present the current scenario in the region, highlighting barriers and possible solutions to encourage its adoption in Latin American countries.Methods An expert panel of 9 Latin American medical pathologists and 1 information technology specialist participated in an online modified Delphi panel, utilizing a third-party platform (iAdvise, Within3, USA). Thirteen pre-prepared questions were answered interactively.Results Experts' observations confirm the paucity of labs in the region that utilize digital pathology technology. The panel ranked obtaining second opinions and presenting images remotely as the main benefit of a digital pathology system, although many others were cited as well. Cost of implantation was the main barrier mentioned by the experts. Payers' and decision makers' lack of awareness of benefits ranked second as a barrier to DP implementation. Internet infrastructure was also mentioned as a concerning issue in the region. Besides diagnostic pathology services, proposed revenue incomes included commercialization of digital services to other institutions, loan agreements of equipment and software, and organizing courses for pathologists or residents. The need for alternative reimbursement methods for diagnostic services was also mentioned. A regional network of collaborating institutions was also suggested as a viable solution to reach distant areas and laboratories lacking the technology.Conclusions The benefits of DP are clear to the expert panel, but cost and lack of awareness of its benefit may be hampering its widespread adoption in Latin America.
“…Among them, immunohistochemistry is the most employed technique in the correlation between p53 protein and the development and progression of malignant neoplasms. However, it provides limited and contradictory data on the actual participation of this molecule in the oral carcinogenesis process (3,8,15,38) .…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.